NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
17/02/2026
Voltar para busca
Dado oficial do USPTO
AAVANTGARDE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
AAVANTGARDE
ST13
US500000098346994Classe
5, 10, 40, 42, 44
Pedido
98346994
Registro
8140404
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
29
Atualização mais recente
17/02/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 10, 40, 42, 44
Data de depósito
08/01/2024
Data de registro
17/02/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
17/02/2026
Última transação
17/02/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
99
Localização do titular
Milan, IT
Examinador
EDWARDS, ALICIA COLLINS
Unidade examinadora
M60
Localização atual
INTENT TO USE SECTION
Titulares e representantes
Titulares
AAVantgarde Bio Srl
Representantes
Scott J. Major Millen White Zelano & Branigan, PC
Classificação técnica
Classes Nice
Classe 5Classe 10Classe 40Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medical and veterinary preparations for therapeutic purposespharmaceutical preparations for treatment of genetic diseases; pharmaceutical preparations for cell therapy; pharmaceutical preparations for gene therapy; pharmaceuticals for the delivery of genes to cellsall for medical purposes; chemical preparations for use in medical sciencein gene therapy and cell therapy; biologic preparations for medical purposesfor use in gene therapy and cell therapy; biologic preparations for use in treatment of genetically based diseases and disorders; gene therapy preparations for use in treatment of genetically based diseases and disorders; gene therapy preparations for medical purposesadeno-associated viral preparations; pharmaceutical preparations in the nature of adeno-associated viral gene therapy preparations; pharmaceutical preparations and substances for the treatment of ocular and otological disorders; biotechnological preparations for the treatment of ocular and otological disorders; pharmaceutical preparations for gene therapy and cell therapy for the treatment of ocular and otological disorders; genetic medicines for the treatment of ocular and otological disorders; biologic preparations for use in the treatment of ophthalmological diseases and disorders; biologic preparations for use in the treatment of blinding and deafness diseases and disorders; biologic preparations for use in the treatment of complement pathway-related or complement pathway-mediated diseases or disorders; gene therapy preparations for use in the treatment of ophthalmological diseases and disorders; gene therapy preparations for use in the treatment of blinding and deafness diseases and disorders; gene therapy preparations for use in the treatment of complement pathway-related or complement pathway-mediated diseases or disorders; adhesive pads for medical and surgical use
Classe 10
Medical and surgical apparatus and instruments for use in gene therapy and cell therapy; medical devices for use in gene therapy and cell therapy; apparatus and instruments for the administration of gene therapy products; ophthalmic surgery devices and instruments; veterinary apparatus and instruments for use in gene therapy and cell therapy; cannulae for use in ophthalmic procedures; needles for surgical and medical purposes; apparatus and instruments for dispensing or delivering preparations into the eye or structures thereof; apparatus and instruments for performing eye surgery; ophthalmic surgery devices and instruments for controlled sub-retinal delivery of pharmaceuticalbiologiccell therapygene therapy products via the suprachoroidal space; medical and veterinary apparatus and instruments for controlled drug delivery during ophthalmic surgery; ophthalmic apparatus and instrumentssurgical instruments for use in delivery and administration of fluidbiologics and pharmaceuticals during ophthalmic proceduresincluding surgery; apparatus and instruments for treating the eyecannulas and needles for obtaining sub-retinal access for delivery of pharmaceutical and biologic preparations in the sub-retinal space; apparatus and instruments for treating the eyecannulas and needles for delivery of pharmaceutical and biologic preparations in the suprachoroidal space; apparatus and instruments for dispensing or delivering preparations into the eye or structures thereofdevices for sub-retinal delivery via suprachoroidal space of pharmaceutical and biologiccell therapy and gene therapy products; with none of the foregoing goods for the purpose of bowel management or collection of bodily waste
Classe 40
Custom manufacturing of pharmaceuticals and pharmaceutical processing; custom manufacturing of biotechnological pharmaceuticals and biopharmaceuticals and processing of biotechnological pharmaceuticals and biopharmaceuticals; biomanufacturing for othersmanufacturing of viral vectors using biological organisms in the manufacturing process; custom manufacturing of pharmaceuticals for gene therapy; pharmaceutical formulation being custom pharmaceutical manufacturing; informationadvice and consultancy services relating to the aforementioned services
Classe 42
Scientific and technological services and research or design relating theretoscientific research in the fields of gene therapy and cell therapy; industrial analysis and research services in the fields of gene therapy and cell therapy; biological and medical product research and development; preclinical and clinical research and development in the fields of gene therapy and cell therapy; gene therapy research; genetic engineeringgene editingthe modification of genetic material in a living organism; genetic medicinegene therapy and genome editing researchdevelopmentanalyticsclinical trials and consultancy relating thereto; biochemical assay development and performancemonitoring of patients prior and subsequent to gene therapy; diagnostics development and performancemonitoring of patients prior and subsequent to gene therapy; biomarker identificationdetection and measurement of biological properties or molecules in the body; manufacturing analytics and manufacturing process designdevelopment and optimisation; scientific research and development services and clinical trials services in relation to pharmaceutical preparations and substances for the treatment of disorders relating to the eye and earbiotechnological preparations for the treatment of disorders relating to the eye and earpreparations for gene therapy and cell therapy for the treatment of disorders relating to the eye and ear and genetic medicines for the treatment of disorders relating to the eye and ear; informationadvice and consultancy services relating to the aforementioned services
Classe 44
Medical services; medical services in the field of genetic or inherited or non-infectious diseases or disorders; medical services in the field of gene therapy or genetic medicine; medical services in the field of gene therapy for ophthalmological diseases and disordersblood disorderslysosomal storage disordersmetabolic disordersinflammatory or immune system disordersrenal and kidney disordershepatological disordersnervous system disorders; medical servicesgene and nucleic acid delivery and modification for therapeutic purposes in the fields of gene therapy and cell therapy; medical servicesgene therapy design and delivery in the fields of gene therapy and cell therapy; medical advisory services relating to gene therapy; provision of a website providing educational information relating to medical servicesgene therapy or genetic medicine; advisoryconsultancy and information services relating to the treatmentrelief and/or prevention of eye and ear diseasesingle gene disordersdiseases of the central and peripheral nervous systemscardiovascular diseasediseases affecting the immune systeminflammatory diseasesinherited diseasediseases of the mouthteethskinhair and earbone and blood diseasesreproductive system disorders; informationadvice and consultancy services relating to the aforementioned services
Publicações
Histórico de despachos e eventos da marca no USPTO.
29 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
17/02/2026
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
29/01/2026
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
29/01/2026
IUCN
NOTICE OF ALLOWANCE CANCELLED
23/10/2025
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
23/10/2025
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
14/10/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
19/08/2025
PUBO
PUBLISHED FOR OPPOSITION
19/08/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
13/08/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/07/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/06/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/06/2025
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
06/06/2025
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
21/01/2025
GNSL
LETTER OF SUSPENSION E-MAILED
21/01/2025
CNSL
SUSPENSION LETTER WRITTEN
21/01/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
18/12/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
18/12/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
18/12/2024
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
18/11/2024
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
18/11/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
19/08/2024
GNRT
NON-FINAL ACTION E-MAILED
19/08/2024
CNRT
NON-FINAL ACTION WRITTEN
19/08/2024
DOCK
ASSIGNED TO EXAMINER
02/08/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
25/04/2024
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
11/01/2024
NWAP
NEW APPLICATION ENTERED
08/01/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace AAVANTGARDE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.